Observed prevalence of AHT in the ASAS-COMOSPA study (Latin America) compared with the expected prevalence in the general population and the prevalence of Global ASAS-COMOSPA for reference.
| Sex | Age, yrs | Observed LA ASAS-COMOSPA | Expected General Population Prevalence (%) | SRR (CI 95%) | Global ASAS-COMOSPA | ||
|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | ||||
| Men | ≤ 24 | 0 | 0 | NA | — | 3 | 2.65 |
| 25–34 | 4 | 12.5 | 3.6 | 3.4 | 49 | 8.47 | |
| 35–44 | 2 | 8.7 | 7.8 | 1.1 | 152 | 24.4 | |
| 45–54 | 6 | 28.5 | 14.6 | 1.9 | 247 | 43.3 | |
| 55–64 | 4 | 57.1 | 30.9 | 1.8 | 240 | 61.1 | |
| ≥ 65 | 7 | 70.0 | NA | — | 201 | 84.1 | |
| Total | 23 | 22.3 | 12.9 | 1.4 (0.9–2.2) | 892 | 34.4 | |
| Women | ≤ 24 | 0 | 0 | NA | — | 0 | 0 |
| 25–34 | 1 | 8.3 | 0.9 | 9.2 | 17 | 7.4 | |
| 35–44 | 2 | 15.3 | 3.8 | 4.0 | 61 | 16.8 | |
| 45–54 | 5 | 41.6 | 17.0 | 2.4 | 132 | 36.8 | |
| 55–64 | 1 | 11.1 | 34.3 | 0.3 | 104 | 45.6 | |
| ≥ 65 | 1 | 25.0 | NA | — | 102 | 68.6 | |
| Total | 10 | 19.6 | 12.1 | 1.5 (0.8–2.8) | 416 | 29.8 | |
| Total (men/women) | 33 | 21.4 | 12.5 | 1.5 (1.0–2.1) | 1308 | 33.1 | |
Hypertension defined as a history of hypertension or antihypertensive therapy use or blood pressure ≥ 140/90 mm Hg at the study visit. LA: Latin America (data confined to patients from Colombia and Mexico); SRR: standardized risk ratio (ratio calculated for the age of 25–64 yrs); n: number with a diagnosis of arterial hypertension (AHT) in each sex and age group; ASAS-COMOSPA: Assessment of SpondyloArthritis international Society of COMOrbidities in SpA; SpA: spondyloarthritis; NA: not available.